Purpose: To inform intervention development, we measured the modifiable determinants of endocrine therapy (ET) non-adherence in women with breast cancer, using the Theoretical Domains Framework (TDF) and examined inter-relationships between these determinants and non-adherence using the Perceptions and Practicalities Approach (PAPA). Methods: Women with stages I-III breast cancer prescribed ET were identified from the National Cancer Registry Ireland (N = 2423) and invited to complete a questionnaire. A theoretically based model of non-adherence was developed using PAPA to examine inter-relationships between the 14 TDF domains of behaviour change and self-reported non-adherence. Structural equation modelling (SEM) was used to test the model...
Thesis (Ph.D.)--University of Washington, 2015Estrogen receptor-positive (ER+) breast cancer is diag...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortal...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Background: Although adjuvant endocrine therapy effectively prevents breast cancer recurrence, nonad...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Purpose: Five to 10years of adjuvant hormonal therapy is recommended to prevent breast cancer recurr...
This is the peer reviewed version of the following article: Brett, J., et. al. (2018). Factors Assoc...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal desp...
Objective: Taking adjuvant hormonal therapy for 5-10 years is recommended to prevent breast cancer r...
Abstract Background Interventions that promote adjuvant endocrine therapy (AET) adherence are critic...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Thesis (Ph.D.)--University of Washington, 2015Estrogen receptor-positive (ER+) breast cancer is diag...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...
Adjuvant endocrine therapy (AET) taken for a minimum of five years reduces the recurrence and mortal...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Background: Although adjuvant endocrine therapy effectively prevents breast cancer recurrence, nonad...
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the r...
Purpose: Five to 10years of adjuvant hormonal therapy is recommended to prevent breast cancer recurr...
This is the peer reviewed version of the following article: Brett, J., et. al. (2018). Factors Assoc...
Jo Brett,1 Mary Boulton,1 Debbie Fenlon,2 Nick J Hulbert-Williams,3 Fiona M Walter,4 Peter Donnelly,...
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be suboptimal desp...
Objective: Taking adjuvant hormonal therapy for 5-10 years is recommended to prevent breast cancer r...
Abstract Background Interventions that promote adjuvant endocrine therapy (AET) adherence are critic...
Introduction : Despite evidence of the efficacy of Adjuvant Endocrine Therapy (AET) in reducing the ...
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast ca...
Thesis (Ph.D.)--University of Washington, 2015Estrogen receptor-positive (ER+) breast cancer is diag...
International audienceAbstract Background Adjuvant endocrine therapy (AET) is a daily oral medicatio...
Purpose: Adherence to adjuvant endocrine therapy (AET) is suboptimal, and a range of variables have ...